baltimore conference logo
  • MJHLS Brand Logo

© 2021 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.

Combining Bevacizumab With EGFR TKIs in Lung Cancer

May 13, 2015
Edward S. Kim, MD

Special Reports, NSCLC (Issue 7), Volume 7, Issue 2

Edward S. Kim, MD, chairman, Solid Tumor Oncology and Investigational Therapeutics, Levine Cancer Institute, Carolinas HealthCare System, discusses combining bevacizumab with EGFR tyrosine kinase inhibitors (TKI) in the treatment of lung cancer.

Edward S. Kim, MD, chairman, Solid Tumor Oncology and Investigational Therapeutics, Levine Cancer Institute, Carolinas HealthCare System, discusses combining bevacizumab with EGFR tyrosine kinase inhibitors (TKI) in the treatment of lung cancer.

<<<

View more from the NSCLC Special Report